Jane Street Group LLC Acquires Shares of 11,141 XBiotech Inc. (NASDAQ:XBIT)

Jane Street Group LLC bought a new position in XBiotech Inc. (NASDAQ:XBIT) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 11,141 shares of the biopharmaceutical company’s stock, valued at approximately $86,000.

Several other institutional investors have also recently added to or reduced their stakes in XBIT. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of XBiotech by 2.2% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 253,770 shares of the biopharmaceutical company’s stock worth $1,962,000 after buying an additional 5,500 shares in the last quarter. State Street Corp increased its holdings in XBiotech by 10.7% during the 3rd quarter. State Street Corp now owns 224,595 shares of the biopharmaceutical company’s stock valued at $1,736,000 after purchasing an additional 21,752 shares in the last quarter. Bank of New York Mellon Corp raised its position in XBiotech by 102.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 98,314 shares of the biopharmaceutical company’s stock valued at $505,000 after purchasing an additional 49,863 shares during the last quarter. American Century Companies Inc. acquired a new position in XBiotech in the second quarter worth $393,000. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of XBiotech by 7.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 58,437 shares of the biopharmaceutical company’s stock worth $452,000 after purchasing an additional 4,298 shares during the last quarter. 55.70% of the stock is owned by institutional investors.

XBiotech Stock Down 3.6 %

XBiotech stock opened at $3.71 on Wednesday. The stock has a 50-day simple moving average of $5.95 and a 200 day simple moving average of $6.49. The stock has a market capitalization of $113.09 million, a price-to-earnings ratio of -3.44 and a beta of 1.44. XBiotech Inc. has a 12-month low of $3.51 and a 12-month high of $9.96.

About XBiotech

XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.